12.05.18

Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategy

Source: Outlook Therapeutics

11.13.18

Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet AMD

Source: Ophthotech

10.27.18

New STAIRWAY Study Data Shows Potential for Extended Durability with Faricimab in Wet AMD

Source: Genentech

10.04.18

Regenxbio Completes Dosing of Fourth Cohort in Phase 1 Trial of RGX-314 Gene Therapy for Wet AMD

Source: Regenxbio

09.25.18

Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluid

Source: Novartis

09.24.18

Bayer, Novartis Lose Case Seeking to End NHS Use of Avastin in Wet AMD

Source: FirstWord

08.17.18

FDA Approves 12-Week Dosing for Eylea in Wet AMD Patients

Source: Regeneron Pharmaceuticals

08.14.18

Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMD

Source: FirstWord

08.09.18

REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data From Ongoing Clinical Trials

Source: REGENXBIO Inc.

07.25.18

Genentech Unveils New Clinical Data For the First Eye Implant for Wet AMD

Source: Genentech

View more stories